The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention

The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention

Authors

  • Christina Kemanetzi Second Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Konstantinos Lallas Oncology Department, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Elisavet Lazaridou Second Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Chrysoula Papageorgiou Second Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Aimilios Lallas First Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Greece
  • Alexandros Stratigos First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece
  • Eleni Timotheadou Oncology Department, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • George Lazaridis Oncology Department, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Dimitrios Dionysopoulos Oncology Department, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Kalliopi Kalaitzi Attikon Hospital, Athens Medical School, Athens, Greece
  • Antonios Tsimpidakis First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece
  • Myrto Trakatelli Second Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Aikaterini Patsatsi Second Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
  • Vasiliki Nikolaou First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece
  • Zoe Apalla Second Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece

Keywords:

checkpoint inhibitors, skin toxicity, skin rash, quality of life, patient reported outcomes

Abstract

Introduction: Data regarding quality of life (QoL) of oncologic patients experiencing dermatologic immune-related adverse events (dirAEs)and their course after dermatologic intervention are scarce.

Objectives To assess the impact of dirAEs on patients' QoL and to investigate the correlation between dermatologic and oncologic indexes used for estimating QoL.

Methods We enrolled oncologic patients with dirAEs managed in two supportive oncodermatology outpatient clinics in Greece. Patient-reported outcomes included DLQI, EORTC-QLQ-C30 and Numerical Rating Scale for pruritus (pNRS).

Results Overall, 110 patients were enrolled in the study. Mean(SD) DLQI and pNRS scores were 15.54 (5.44) and7.25 (2.95), correspondingly, while functional, symptom and summary scores of EORTC-C30 were 79.17 (2.11), 17.66 (3.60) and 80.67 (3.08), respectively. After therapeutic interventions, there was a statistically significant decrease in DLQI scores after1st intervention compared to baseline, and 2nd intervention compared to 1st [mean (SD) decrease 4.38 (2.91), p<0.001 and 5.16 (3.99), p<0.001, respectively]. DLQI showed no correlation with global health status/QoLs (rho 0.01, p=0.90) of EORTC-C30.

Conclusions dirAEs negatively affect QoL. Dermatologic intervention improves patients’ QoL, facilitating an unimpaired oncologic treatment. Poor correlation between DLQI and EORTC-QLQ-30 highlights the need for adapted QoL measurement tools in the context of ICIs treatment.  

References

Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35: 785-792.

Haanen J, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: 119–42.

Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–32.

Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254–63.

Merli M, Accorinti M, Romagnuolo M, et al. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Front Med (Lausanne). 2023;10:1208418.

Dika E, Lambertini M, Gouveia B, , et al. Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies. J Clin Med. 2021;10(6):1283.

Hua C, Boussemart L, Mateus C et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol 2016; 152: 45–51.

Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 2015; 151: 1206–12.

Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes Nivolumab in Metastatic Melanoma: irAE Relation to Survival. Clin Cancer Res 2016; 22: 886–94.

Nagao A, Takei Y, Ogawa Y, Shimada M, Tanigawa K, Suzuki S. Examination of the quality of life in the cancer patients under immunotherapy. Gan To Kagaku Ryoho 2012; 39: 1785–7.

Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med [Internet]. 2016 Oct 4 [cited 2020 Oct 15];4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052926/

O’Reilly A, Hughes P, Mann J et al. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support Care Cancer 2020; 28: 561–70.

Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6.

Cella D, Grünwald V, Nathan P et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Onco. 2016; 17: 994–1003.

Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365–76.

De Luca R, Coco GL, Addeo R et al. Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab). World J Oncol 2021; 12: 104.

Barbu MA, Niţipir C, Voiosu T, Giurcăneanu C. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study. Rom J Intern Med 2018; 56: 96–101.

Mazieres J, Kowalski D, Luft A et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer. J Clin Oncol 2020; 38: 271-280.

Ooki, A, Morita S, Tsuji A, et al. Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. Cancer Med 2000; 9: 9419-9430.

Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27-33.

Chen ST, Molina GE, Lo JA et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study. J Am Acad Dermatol 2020; 82: 994–6.

Walocko FM, Ly BC, White MS, Chen SC, Yeung H. Health-related quality of life measures and immune checkpoint inhibitors: a systematic review. J Am Acad Dermatol 2020; 82: 1004–6.

Barrios DM, Phillips GS, Freites-Martinez A et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J EurAcad Dermatol Venereol 2020; 34: 1340–1347.

Boutros A, Bruzzone M, Tanda ET et al. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in andomized controlled trials: A systematic review and meta-analysis. Eur J Cancer 2021; 159: 154–66.

Rapoport BL, van Eeden R, Sibaud V et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer 2017; 25: 3017-3030.

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-1982.

Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375–91.

Basch E, Deal AM, Kris MG et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol Off J Am Soc Clin Oncol 2016; 34: 557–65.

Basch E, Deal AM, Dueck AC et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA 2017; 318: 197–8.

Downloads

Published

2024-07-31

How to Cite

1.
The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention. Dermatol Pract Concept [Internet]. 2024 Jul. 31 [cited 2024 Dec. 5];14(3):e2024118. Available from: https://www.dpcj.org/index.php/dpc/article/view/3884

Share